EP3908291A4 - Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems - Google Patents

Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems Download PDF

Info

Publication number
EP3908291A4
EP3908291A4 EP20737913.2A EP20737913A EP3908291A4 EP 3908291 A4 EP3908291 A4 EP 3908291A4 EP 20737913 A EP20737913 A EP 20737913A EP 3908291 A4 EP3908291 A4 EP 3908291A4
Authority
EP
European Patent Office
Prior art keywords
ubiquitin ligase
dtag
fkbp12
lindau
vhl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20737913.2A
Other languages
German (de)
French (fr)
Other versions
EP3908291A1 (en
Inventor
Nathanael S. Gray
Fleur M. FERGUSON
Behnam NABET
Dennis L. BUCKLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP3908291A1 publication Critical patent/EP3908291A1/en
Publication of EP3908291A4 publication Critical patent/EP3908291A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8536—Animal models for genetic diseases
EP20737913.2A 2019-01-07 2020-01-06 Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems Pending EP3908291A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789230P 2019-01-07 2019-01-07
PCT/US2020/012348 WO2020146250A1 (en) 2019-01-07 2020-01-06 SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS

Publications (2)

Publication Number Publication Date
EP3908291A1 EP3908291A1 (en) 2021-11-17
EP3908291A4 true EP3908291A4 (en) 2023-01-11

Family

ID=71520863

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20737913.2A Pending EP3908291A4 (en) 2019-01-07 2020-01-06 Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems

Country Status (5)

Country Link
US (1) US20220089589A1 (en)
EP (1) EP3908291A4 (en)
AU (1) AU2020205952A1 (en)
CA (1) CA3126009A1 (en)
WO (1) WO2020146250A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355764A1 (en) * 2020-09-13 2023-11-09 Shandong Boan Biotechnology Co., Ltd. Downregulation of membrane-bound proteins by receptor tac technology
WO2023150649A2 (en) * 2022-02-02 2023-08-10 Outpace Bio, Inc. Synthetic degrader system for targeted protein degradation
WO2023172889A1 (en) * 2022-03-07 2023-09-14 The University Of North Carolina At Chapel Hill Use of chemical epigenetic modifiers to modulate gene expression
CN114874132B (en) * 2022-05-24 2023-06-06 无锡捷化医药科技有限公司 Preparation method of recombinant human receptor protein FKBP12 ligand

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2018148440A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018148443A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633386B2 (en) * 2016-04-12 2020-04-28 The Regents Of The University Of Michigan BET protein degraders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2018148440A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018148443A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] 1 January 2017 (2017-01-01), BRADNER JAMES ;: "Using heterobifunctional compounds for targeted CAR protein degradation to attenuate adoptive immunotherapy associated adverse inflammation - WO 2017024318 A1", XP055952197, retrieved from ACS Database accession no. 2017:229794 *
DATABASE CAPLUS [online] 1 January 2017 (2017-01-01), BRADNER JAMES ;: "Using heterobifunctional compounds for targeted CAR protein degradation to attenuate adoptive immunotherapy associated adverse inflammation - WO 2017024318 A1", XP055952509, retrieved from ACS Database accession no. 2017:229794 *
DATABASE CAPLUS [online] 1 January 2017 (2017-01-01), BRADNER JAMES: "Methods to induce targeted protein degradation through bifunctional molecules - WO 2017024317 A2", XP055952510, retrieved from ACS Database accession no. 2017:229795 *
DATABASE CAPLUS [online] 1 January 2018 (2018-01-01), BRADNER JAMES: "Regulating CAR-cells against inflammatory side effects by targeted CAR protein degradation through the use of ubiquitin ligase binding heterobifunctional compounds - WO 2018148440 A1", XP055952511, retrieved from ACS Database accession no. 2018:1504369 *
DATABASE REAXYS [online] Elsevier; 16 August 2018 (2018-08-16), BUCKLEY D: "TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS - WO2018/148443 A1", XP055952184, Database accession no. XRN = 33551764 *
PHILIPP OTTIS ET AL: "Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation", ACS CHEMICAL BIOLOGY, vol. 12, no. 10, 5 September 2017 (2017-09-05), pages 2570 - 2578, XP055618965, ISSN: 1554-8929, DOI: 10.1021/acschembio.7b00485 *

Also Published As

Publication number Publication date
EP3908291A1 (en) 2021-11-17
WO2020146250A1 (en) 2020-07-16
AU2020205952A1 (en) 2021-06-17
US20220089589A1 (en) 2022-03-24
CA3126009A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
EP3908291A4 (en) Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems
EP3908224A4 (en) Systems and methods for aligning inputs on medical instruments
EP3923098A4 (en) Work assistance system, information processing device, and work assistance method
EP4028168A4 (en) Systems and methods using pipettes for performing chemical and/or biological processes
EP3469537A4 (en) Methods and systems for processing and displaying review data based on one or more stored relationship associations and one or more rule sets
EP3260816A4 (en) Information processing system, on-vehicle device, and terminal device
EP3786793A4 (en) Task processing method and device, and computer system
EP3413230A4 (en) Information processing device, information processing method, and distributed component
EP3961423A4 (en) Information processing method, information processing device, and information processing system
EP3944680A4 (en) Clock offset determination method, clock offset processing method, device, and system
EP3144786A4 (en) Method, system for processing fingerprint input information and mobile terminal
EP3446563A4 (en) Information processing server, information processing system, and information processing method
EP3317440A4 (en) Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
EP3908041A4 (en) Cell switching method and device, and user processing method and device
EP3494477A4 (en) Information processing system, client terminal, and control method
EP3736763A4 (en) Information processing device, analyzer, and information processing system
EP3774025A4 (en) System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
EP3876505A4 (en) Terminal case, gripping device and information processing device
EP4050892A4 (en) Work assist server, work assist method, and work assist system
EP3941079A4 (en) Information processing device, regeneration processing device, information processing method, and regeneration processing method
EP3933383A4 (en) Information processing device, information processing method, and information processing system
EP3870370A4 (en) Sample vials, rack mounts and sampling devices using them
EP3952122A4 (en) Information processing device, information processing system, terminal device, and information processing method
EP4083844A4 (en) Information processing device, information processing system, and information processing method
EP3959341A4 (en) Methods and systems for microsatellite analysis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/725 20060101ALI20220901BHEP

Ipc: C12N 9/90 20060101ALI20220901BHEP

Ipc: C12N 9/10 20060101ALI20220901BHEP

Ipc: A61P 35/00 20060101ALI20220901BHEP

Ipc: A61K 38/00 20060101ALI20220901BHEP

Ipc: A61K 47/55 20170101ALI20220901BHEP

Ipc: C07K 14/82 20060101ALI20220901BHEP

Ipc: C12N 9/22 20060101ALI20220901BHEP

Ipc: A61K 35/17 20150101AFI20220901BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221208

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/725 20060101ALI20221202BHEP

Ipc: C12N 9/90 20060101ALI20221202BHEP

Ipc: C12N 9/10 20060101ALI20221202BHEP

Ipc: A61P 35/00 20060101ALI20221202BHEP

Ipc: A61K 38/00 20060101ALI20221202BHEP

Ipc: A61K 47/55 20170101ALI20221202BHEP

Ipc: C07K 14/82 20060101ALI20221202BHEP

Ipc: C12N 9/22 20060101ALI20221202BHEP

Ipc: A61K 35/17 20150101AFI20221202BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230911